AR132340A1 - Compuestos tricíclicos para el tratamiento de cáncer - Google Patents
Compuestos tricíclicos para el tratamiento de cáncerInfo
- Publication number
- AR132340A1 AR132340A1 ARP240100854A ARP240100854A AR132340A1 AR 132340 A1 AR132340 A1 AR 132340A1 AR P240100854 A ARP240100854 A AR P240100854A AR P240100854 A ARP240100854 A AR P240100854A AR 132340 A1 AR132340 A1 AR 132340A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer treatment
- tricyclic compounds
- compounds
- tricyclic
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (1), en donde R¹ a R⁴, A¹, A², M y L son como se describe en la presente, y su sal farmacéuticamente aceptable de estos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023086590 | 2023-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132340A1 true AR132340A1 (es) | 2025-06-18 |
Family
ID=90721049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100854A AR132340A1 (es) | 2023-04-06 | 2024-04-05 | Compuestos tricíclicos para el tratamiento de cáncer |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4688791A1 (es) |
| JP (1) | JP2026515652A (es) |
| CN (1) | CN120917030A (es) |
| AR (1) | AR132340A1 (es) |
| TW (1) | TW202446387A (es) |
| WO (1) | WO2024208934A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4596552A1 (en) | 2022-09-29 | 2025-08-06 | Guangzhou Joyo Pharmatech Co., Ltd | Macrocyclic derivative and use thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025201453A1 (en) * | 2024-03-28 | 2025-10-02 | Beigene (Suzhou) Co., Ltd. | Macrocyclic compounds as ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026022119A1 (en) * | 2024-07-24 | 2026-01-29 | F. Hoffmann-La Roche Ag | Ras inhibitors in combination therapy for use in treating cancers |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026082180A1 (zh) * | 2024-10-18 | 2026-04-23 | 合肥盛浦医药科技有限公司 | 一种大环化合物、其中间体、其制备方法及其应用 |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119874607B (zh) * | 2025-01-16 | 2025-11-21 | 南京艾康生物科技有限公司 | 一种1-boc-2,2-二甲基哌啶-4-酮的制备方法 |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021091956A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4208261A1 (en) * | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CN117979966A (zh) * | 2021-04-09 | 2024-05-03 | 锐新医药公司 | 使用sos1抑制剂和ras抑制剂治疗癌症 |
| PE20240088A1 (es) * | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| WO2022251292A1 (en) * | 2021-05-25 | 2022-12-01 | Revolution Medicines, Inc. | Methods for inhibiting ras |
-
2024
- 2024-04-03 TW TW113112772A patent/TW202446387A/zh unknown
- 2024-04-04 WO PCT/EP2024/059114 patent/WO2024208934A1/en not_active Ceased
- 2024-04-04 JP JP2025558121A patent/JP2026515652A/ja active Pending
- 2024-04-04 CN CN202480023172.2A patent/CN120917030A/zh active Pending
- 2024-04-04 EP EP24718367.6A patent/EP4688791A1/en active Pending
- 2024-04-05 AR ARP240100854A patent/AR132340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202446387A (zh) | 2024-12-01 |
| CN120917030A (zh) | 2025-11-07 |
| JP2026515652A (ja) | 2026-05-19 |
| EP4688791A1 (en) | 2026-02-11 |
| WO2024208934A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2025001184A2 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CO2024017733A2 (es) | Inhibidores macrocíclicos de kras para el tratamiento de cáncer | |
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| AR133266A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| PE20241299A1 (es) | Derivados de exatecan y sus conjugados anticuerpo-farmaco | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20220140A1 (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos | |
| PE20251323A1 (es) | Compuestos triciclicos y sus usos | |
| MX394700B (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
| UY39574A (es) | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene | |
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| ECSP11010804A (es) | Compuestos orgánicos | |
| DOP2024000102A (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa | |
| CL2024002479A1 (es) | Compuestos derivados de diciclopropilo, moduladores de il-17a, y usos de estos. | |
| AR130984A1 (es) | Compuestos novedosos | |
| AR131006A1 (es) | Compuestos novedosos | |
| BR112022019888A2 (pt) | Compostos tricíclicos como inibidores de egfr | |
| PE20240776A1 (es) | Compuestos terapeuticos y procedimientos | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| AR133167A1 (es) | Macrociclos para el tratamiento de enfermedad autoinmunitaria |